BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
December 12, 2023 09:15 ET
|
BioRestorative Therapies, Inc
--Notice of allowance will be the fourth U.S. patent granted under Company’s ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Dec. 12, 2023 ...
BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City
October 09, 2023 12:10 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics
September 12, 2023 09:00 ET
|
BioRestorative Therapies, Inc
--BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to Supply Biologics for Cosmetic Applications in Strategic Agreement --Agreement Represents Initial Venture into...
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
September 08, 2023 08:30 ET
|
BioRestorative Therapies, Inc
--Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— --15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE,...
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
July 11, 2023 08:30 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
June 27, 2023 07:00 ET
|
BioRestorative Therapies, Inc
No Dose Limiting Toxicity (DLT) was Observed in the Patients in the Safety Run-In Segment of StudyDSMB Recommendation Allows for Open Enrollment MELVILLE, N.Y., June 27, 2023 (GLOBE NEWSWIRE) --...
BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 16, 2023 07:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
June 12, 2023 07:00 ET
|
BioRestorative Therapies, Inc
--Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100-- MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) --...
BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference
June 01, 2023 09:15 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
May 31, 2023 07:00 ET
|
BioRestorative Therapies, Inc
--License will enable expanded clinical operations for investigator-initiated trials and potential “right to try” uses of BRTX-100.— MELVILLE, N.Y., May 31, 2023 (GLOBE NEWSWIRE) --...